Biomarkers and Pe...
Follow
Find tag "kras"
11.9K views | +0 today
Biomarkers and Personalized Medicine
Sharing relevant articles on advancements in personalized medicine
Curated by Brian Shields
Your new post is loading...
Your new post is loading...
Scooped by Brian Shields
Scoop.it!

BATTLE-2: Next-Generation of Biomarker-Driven Trials - OncLive

BATTLE-2: Next-Generation of Biomarker-Driven Trials - OncLive | Biomarkers and Personalized Medicine | Scoop.it
OncLive BATTLE-2: Next-Generation of Biomarker-Driven Trials OncLive While the number of known mutations and matching targeted agents is relatively limited at present, clinical trials are being designed to identify effective therapies for specific...
Brian Shields's insight:

The next-generation of clinical trials...Powerful quote in this article from Dr. Roy Herbst:


Are clinical trials like this going to be the wave of the future for developing new cancer therapies?

Herbst: Absolutely. I think it’s essential. If you don’t let the biology drive the treatment, everything is empiricism and it is going to have a very low chance of hitting the mark. So absolutely, as Dr Wistuba said, treat patients the best you can in real time, but also learn, discover, identify new markers.



This trial uses biomarkers to guide decisions, thereby providing patients with the best possible treatment arm, despite randomization.

more...
Nalina Nagarajan's curator insight, April 17, 2013 12:14 PM

A necessary development !!

Scooped by Brian Shields
Scoop.it!

Matching Tumors With The Optimal Cancer Drugs - Science 2.0

Matching Tumors With The Optimal Cancer Drugs - Science 2.0 | Biomarkers and Personalized Medicine | Scoop.it
Matching Tumors With The Optimal Cancer Drugs
Science 2.0
The main driver of pancreatic cancer, a mutation in a gene called KRAS, has proven difficult to target with treatments.
Brian Shields's insight:

Very Powereful Quote and an important one for clinicians to understand, " We have a small but effective inventory of 'druggable' mutations that we know play a role in cancer"

more...
No comment yet.
Scooped by Brian Shields
Scoop.it!

New Drug Is First to Help Patients With Recurrent Low-Grade Ovarian Cancer - Science Daily (press release)

New Drug Is First to Help Patients With Recurrent Low-Grade Ovarian Cancer Science Daily (press release) Cancer-causing genetic mutations in BRAF and KRAS genes occur more frequently in low-grade ovarian cancer, so the researchers chose a drug that...
Brian Shields's insight:

Researchers identified that KRAS and BRAF mutations occur more frequently in low grade Ovarian cancer and chose a therapy (Selumetinib) that inhibits the molecular network, MAPK, that includes these genes. 


The outcome:


"These are remarkably encouraging results for what can ultimately be a devastating disease," said Gershenson, the paper's senior author.

more...
Erin Grills's curator insight, February 23, 2013 10:04 PM

This site will allow me to discuss the advancements in drugs for my pharmaceutical subtopic. This also allows me to expand my research to see how many other cancer drugs are being discovered due to the advancemens in engineering.